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Abstract
Background:  Bacillus Calmette Guérin (BCG)-immunotherapy has a well-documented and
successful clinical history in the treatment of bladder cancer. However, regularly observed side
effects, a certain degree of nonresponders and restriction to superficial cancers remain a major
obstacle. Therefore, alternative treatment strategies are intensively being explored.
We report a novel approach of using a well defined immunostimulatory component of
Mycobacterium tuberculosis for the treatment of bladder cancer. The phosphate transport protein
PstS1 which represents the phosphate binding component of a mycobacterial phosphate uptake
system is known to be a potent immunostimulatory antigen of M. tuberculosis. This preclinical study
was designed to test the potential of recombinant PstS1 to serve as a non-viable and defined
immunotherapeutic agent for intravesical bladder cancer therapy.
Methods: Mononuclear cells (PBMCs) were isolated from human peripheral blood and stimulated
with PstS1 for seven days. The activation of PBMCs was determined by chromium release assay,
IFN-γ ELISA and measurement of lymphocyte proliferation. The potential of PstS1 to activate
monocyte-derived human dendritic cells (DC) was determined by flow cytometric analysis of the
marker molecules CD83 and CD86 as well as the release of the cytokines TNF-α and IL-12.
Survival of presensitized and intravesically treated, tumor-bearing mice was analyzed by Kaplan-
Meier curve and log rank test. Local and systemic immune response in PstS1-immunotherapy was
investigated by anti-PstS1-specific ELISA, splenocyte proliferation assay and immunohistochemistry.
Results: Our in vitro experiments showed that PstS1 is able to stimulate cytotoxicity, IFN-γ release
and proliferation of PBMCs. Further investigations showed the potential of PstS1 to activate
monocyte-derived human dendritic cells (DC). In vivo studies in an orthotopic murine bladder
cancer model demonstrated the therapeutic potential of intravesically applied PstS1.
Immunohistochemical analysis and splenocyte restimulation assay revealed that local and systemic
immune responses were triggered by intravesical PstS1-immunotherapy.
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Conclusion: Our results demonstrate profound in vitro activation of human immune cells by
recombinant PstS1. In addition, intravesical PstS1 immunotherapy induced strong local and systemic
immune responses together with substantial anti-tumor activity in a preclinical mouse model. Thus,
we have identified recombinant PstS1 antigen as a potent immunotherapeutic drug for cancer
therapy.
Background
Urothelial carcinoma of the bladder accounts for about
4% of all cancer related death in man. The large majority
of tumors (70–80%) is superficial at diagnosis and has a
high rate of local recurrence (70%) and progression
(30%) after local surgical therapy. Therefore, patients
require lifelong medical follow-up examinations and
effective prophylactic treatment to prevent recurrences
and progression of the tumor.
In this type of cancer, the immunotherapeutic use of
Mycobacteria – specifically Bacillus Calmette-Guerin
(BCG), a non-pathogenic strain of Mycobacterium bovis –
has a well-documented and successful clinical history.
Immunotherapy with BCG is performed by six weekly
instillations of viable Mycobacteria (for induction course)
into the bladder of patients after initial transurethral
resection of the tumor. Until now various clinical trials
have shown that this type of therapy is superior to topical
chemotherapy and transurethral resection of the tumor
alone to prevent recurrences and local progression espe-
cially in patients with high risk tumors [1-3]. Despite sev-
eral clear advantages of BCG immunotherapy for the
treatment of bladder cancer, several problems and limita-
tions compromise its use. Although BCG is the most effec-
tive agent against superficial transitional cell carcinoma
(TCC), currently there are still 30 to 40% of patients not
responding to the therapy [4]. Furthermore, in the case of
muscle invasive bladder cancer, BCG has not been shown
to be effective [5]. BCG's activity appears to be strictly
localized and as a living organism, BCG poses unique tox-
icity problems associated with its use. Although only 5%
of these problems are severe, most if not all patients expe-
rience some irritable bladder symptoms (cystitis) during
BCG therapy [6]. Roughly 40% develop hematuria and
30% experience flu-like symptoms including fever,
malaise and nausea or vomiting. Actual BCG sepsis is a
rare event and has been reported in only 0.4% of all cases.
In addition, some of these cases have been fatal [7,8].
Thus, the reported side effects limit the clinical applicabil-
ity and acceptance of this effective immunotherapy and
underscore the need for alternative forms of treatment.
In order to limit toxicity recent endeavors are therefore
focused on the development of alternative non-viable
products and some of those have already been tested in
preclinical and clinical studies [9-12]. The mycobacterial
antigen PstS1 is known as a highly immunogenic and
immunostimulatory component of the mycobacterial cell
membrane [13]. PstS1 is the phosphate binding subunit
of the inorganic phosphate uptake system from M. tuber-
culosis belonging to the family of ABC (ATP-binding cas-
sette) transporters [14,15]. It is a glycosylated lipoprotein
which can be found both, intracellularly and secreted into
the extracellular culture supernatant [16,17]. Moreover
PstS1 represents one of the most immunogenic antigens
in active multibacillary tuberculosis [18].
We hypothesized that this highly immunogenic protein
antigen could function as an effective biological response
modifier in immunotherapy of bladder cancer. To test the
tumortherapeutic potential of recombinantly expressed
PstS1 [19] we performed a detailed analysis of the immu-
nostimulatory capacity of this antigen in a well-defined
human  in vitro system and in a previously described
murine model of experimental bladder cancer therapy
[20]. Because the role of prior exposure of bladder cancer
patients to mycobacterial antigens for the effectiveness of
BCG therapy is controversely discussed [21-23], we per-
formed intravesical PstS1-immunotherapy with and with-
out prior sensitization of mice.
The data reported herein demonstrate that PstS1 is a
potent activator of human tumor-cytotoxic MNCs,
induces maturation and activation of human dendritic
cells and most importantly is very effective in the treat-
ment of experimental orthotopic bladder cancer. While
local and systemic immune responses were observed in
sensitized and non-sensitized mice, immunotherapy of
cancer was only successful in non-sensitized animals.
Methods
Cell culture
The human bladder tumor cell line T-24 was cultured at
37°C and 5% CO2 in RPMI 1640 (PAA Laboratories, Linz/
Austria) containing 10% FCS (Linaris, Bettingen/Ger-
many), 1% glutamine, 100 U/ml penicillin and 100 µg/
ml streptomycin. The murine bladder tumor cell line MB-
49 was cultured at 37°C and 5% CO2 in DMEM (PAA Lab-
oratories, Linz/Austria) containing 10% FCS (Linaris, Bet-
tingen/Germany), 1% L-glutamine, 100 U/ml penicillin
and 100 µg/ml streptomycin.BMC Cancer 2004, 4:86 http://www.biomedcentral.com/1471-2407/4/86
Page 3 of 14
(page number not for citation purposes)
Stimulation of human PBMCs
MNCs from heparinized blood of healthy human donors
were obtained by discontinuous gradient centrifugation
using Biocoll Separating Solution (Biochrom, Berlin/Ger-
many) and adjusted to a concentration of 1 × 106/ml in
RPMI-1640 medium containing 5% human serum, 100
U/ml penicillin and 100 µg/ml streptomycin. Recom-
binant PstS1 in concentrations from 0.1 µg/ml – 100 µg/
ml, BCG (Connaught substrain, Immucyst, 4 × 104 cfu/
ml), or PBS (100 µl) was added and the cells were cultured
for 7 days in 6-well microtiter plates at 37°C and 5% CO2.
Chromium release assay
Cytotoxicity was determined in a standard 4-hour chro-
mium release assay. Target cells were labeled with
Na2
51CrO4 (ICN, Irvine/USA) for 1 h at 37°C, washed and
resuspended at 5 × 104 cells/ml. Effector cells were added
to a total of 100 µl of target cells at an effector:target ratio
of 40:1. The radioactive content of the supernatant was
measured in a gamma-counter (Berthold, Wildbad/Ger-
many). The specific lysis was determined according to the
formula: spec. lysis (%) = 100 × (Exp – Spo)/ (Max – Spo)
where Exp is the experimental release, Spo the spontane-
ous release and Max the maximum release.
Human IFN-γ ELISA
Supernatants of PstS1, BCG and PBS stimulated PBMCs
were recovered at days 2, 5 or 7 and examined for the pres-
ence of IFN-γ. Each experiment was carried out several
times with different donors. Detection was performed
with an anti human IFN-γ ELISA-Kit according to the
manufacturers' instructions (eBioscience, San Diego/
USA).
Proliferation of human PBMC
PBMCs were stimulated for 2 to 7 days with PstS1, BCG,
PBS or PHA (Sigma). 2 × 105 cells / well of the stimulated
PBMCs were cultured in a microwell plate and 1 µCi 3H-
Thymidine (five wells per sample) (Amersham, Freiburg/
Germany) was added during the last 18 h of stimulation.
DNA was harvested on filter membranes and thymidine
incorporation was measured by liquid scintillation count-
ing (counter: LKB Wallace 1205 beta-plate, Turku/Fin-
land).
Generation and stimulation of human monocyte derived 
dendritic cells
After separating peripheral blood mononuclear cells
(PBMCs) from heparinized blood of healthy donors by
Ficoll-Paque centrifugation, monocytes were elutriated by
counterflow centrifugation. For generation of immature
DCs, 2 × 106 monocytes were cultured for seven days with
2 ml RPMI 1640, 10% FCS (Linaris, Bettingen/Germany)
1% penicillin/streptomycin and IL-4/GM-CSF (500 U/ml
each) (TEBU/PeproTech, Offenbach/Germany) in 24-well
cell culture plates (Nunc, Wiesbaden/Germany).
Exchange of medium was carried out at day three and day
five. This procedure resulted in full differentiation of
monocytes with no undifferentiated monocytes present in
the cultures after seven days. Immature DCs were stimu-
lated for three days with 10 µg/ml PstS1 or BCG (MOI =
0.01) and subjected to flow cytometry. Debris was
excluded from the analysis according to FSC/SSC gating.
Flow cytometry
Expression of cell surface molecules was analyzed by flow
cytometry (FACSCalibur, Becton Dickinson, Franklin
Lakes/USA) using phycoerythrin (PE) conjugated mono-
clonal antibodies (mAbs): anti-CD1a (Biosource,
Camarillo/USA), anti-CD83 (Pharmingen, San Diego/
USA), anti-CD14 and anti-CD86 (Dianova, Hamburg/
Germany).
1 × 105 DCs suspended in PBS containing 5% human
serum and 0.1 % sodium acide were incubated with mAbs
for 30 minutes on ice. Then cells were washed with PBS
and resuspended in 400 µl 1.5 % paraformaldehyde in
PBS.
human TNF-α and IL-12 ELISA
Supernatants of PstS1, BCG and PBS stimulated DCs were
recovered at day 3 after stimulation and examined for the
presence of TNF-α and IL-12. Each experiment was carried
out several times with different donors. TNF-α detection
was performed with a quantitative ELISA, provided by Dr.
H. Gallati (Intex, Muttenz/Switzerland).
IL-12 detection was carried out with an ELISA-Kit from
eBioscience (San Diego/USA).
PLG-Particle preparation and protein loading
PLG-particles (10 mg/ml) (Lionex, Braunschweig/Ger-
many) were diluted 4:1 with PBS and the pH was adjusted
to 7.0 with NaOH. PstS1 was recombinantly expressed in
E. coli and purified by standard chromatography.
250 µg of PLG-particles were loaded with PstS1 or BSA by
coincubation with 60 µg of the respective protein for 15 h
at RT on a shaker (overall volume 100 µl). Afterwards the
particles were spun down and washed for 5 min with 100
µl PBS. The supernatant was removed and the particles
were diluted in 100 µl of PBS. 10 µl of loaded particle
solution were centrifuged and the pellet was treated for 30
min at RT with 0.1 M NaOH/ 10% SDS. After centrifuga-
tion in a minifuge, supernatant was removed and ana-
lyzed on a 10% SDS page. Using recombinant PstS1 as a
calibration standard it was determined that 250 µg PLG-
particles bound approximately 50 µg of PstS1 protein.BMC Cancer 2004, 4:86 http://www.biomedcentral.com/1471-2407/4/86
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PLG-particle vaccination and immunotherapy of 
experimental bladder cancer
Female C57BL/6 mice were purchased from Charles-River
Laboratories (Sülzfeld/ Germany) at the age of 6–8 weeks.
To test efficacy of PstS1 therapy in C57/BL6 mice a pub-
lished syngeneic, orthotopic bladder cancer model was
used [10]. Trial I: 15 animals per group were subcutane-
ously injected with 250 µg PLG-particles coated with 50
µg PstS1 or 250µg PLG-particles alone. Ten days later the
mice were anesthetized by intraperitoneal treatment with
Pentobarbital (0.067 mg/g body weight). After insertion
of a 24-gauge teflon intravenous catheter (Insyte-W, Bec-
ton Dickinson, Franklin Lakes/USA) transurethrally into
the bladder, electrocoagulation was performed with a
guide wire. Thereafter 6 × 104 MB-49 cells were instilled
into the bladder. Intravesical immunotherapy with 100 µg
PstS1 in 100 µl PBS was performed on days 1, 8, 15 and
22 after tumor implantation. Control groups were
instilled with PBS (100 µl) alone. The viability status of
the mice was checked daily. Surviving mice were sacrificed
on day 70. Survival of mice was compared using Kaplan-
Meier analysis and log-rank test. Trial II: Performance sim-
ilar to trial I with the following differences. 11 animals per
group were subcutaneously injected with a) 250 µg empty
PLG-particles b) 250 µg PLG-particles coated with 50 µg
BSA c) 100µl of PBS. Intravesical treatments were per-
formed with 100 µg PstS1 or PBS only.
Immunohistochemistry of murine bladders
C57/BL6 mice (5 per group) were treated as described in
table I. One day after the fourth instillation animals were
sacrificed. Bladders were dissected immediately, shock-
frozen in liquid nitrogen and stored at -80°C. The immu-
nohistochemistry and analysis of cellular influx of differ-
ent leukocyte subsets was performed on 5µm frozen
sections as described previously [24].
anti-PstS1-IgG ELISA from murine blood
Murine blood was obtained immediately after sacrificing
mice by heart punctation and centrifuged in a microcen-
trifuge to obtain the serum for antibody analysis which
was performed with the PstS1-ELISA-kit (Lionex GmbH,
Braunschweig/Germany) according to the manufacturer's
instructions.
Splenocyte restimulation assay
Splenocytes were isolated, washed with PBS and erythro-
cytes were lysed with H2O. Afterwards 2 × 105 cells / well
were cultured in a microwell plate and stimulated with 10
µg/ml PstS1 for a period of five days (five wells per sam-
ple). Then 1µCi 3H-Thymidine (Amersham, Freiburg/Ger-
many) was added and cells were incubated for 15 h at
37°C and 5% CO2. Finally the DNA was harvested on fil-
ter membranes and 3H-Thymidine incorporation was
measured by liquid scintillation counting (counter: LKB
Wallace 1205 beta-plate, Turku/Finland).
Results
PstS1 activates human PBMCs
To assess the immunostimulatory properties of our PstS1-
preparation we analyzed several human PBMC in vitro sys-
tems. As in these systems the immunostimulatory mecha-
nisms of whole BCG bacteria have been thoroughly
studied in the past [9,25-27] we used BCG as a positive
control and reference stimulus.
In a first set of experiments the optimal concentration of
PstS1 to stimulate human PBMC cytotoxicity (Fig. 1A),
IFN-γ release (Fig. 1B) and proliferation (Fig. 1C) was
determined. Using a concentration range from 0.1 µg/ml
to 100 µg/ml PstS1 showed a typical bell-shaped dose
response curve. A concentration of 10 µg/ml was found to
be optimal for stimulation of human PBMC in all three
readout systems. In order to analyze the time course of
human PBMC activation, a time kinetic study of PBMC
stimulation was performed. BCG, which has been previ-
ously described to induce potent anti-tumor cytotoxicity
in human PBMCs [27] was used as a reference stimulus
and positive control.
As depicted in figure 2A,2B,2C activation of human PBMC
by PstS1 was time-dependent with the strongest activation
on day 7 and only marginal activation at early time points
(day 2). Overall, in this study we have tested the activation
of PBMC of ten different human donors in response to
PStS1 stimulation. As expected, we observed a certain
degree of donor variability in this assays with e.g. IFN-γ
induction ranging from 500 pg/ml to 5 ng/ml. Compari-
son with BCG consistently indicates a similar time-kinetic
of PBMC activation between these two biological
response modifiers albeit with higher absolute levels of
activation induced by BCG. This kinetic of activation is
Table 1: Serum antibody response after PstS1 immunotherapy
S.C. / Intravesical Treatment Responders in %
PBS/PBS 0
L-Particle/PBS 0
L-Particle-PstS1/PBS 100
PBS/PstS1 100
L-particle/PstS1 100
L-particle-PstS1/PstS1 100
Five mice per group were sensitized s.c. and treated intravesically on 
days 10, 17, 24 and 31 as indicated in the table. On day 32 serum of 
mice was obtained and analyzed for anti-PstS1 IgG by ELISA. The 
percentage of mice with positive anti-PstS1 antibody responses is 
indicated.BMC Cancer 2004, 4:86 http://www.biomedcentral.com/1471-2407/4/86
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Activation of PBMC by PstS1 is dose-dependent Figure 1
Activation of PBMC by PstS1 is dose-dependent. PBMCs were stimulated for 7 days with different PstS1 concentrations 
in a range from 0.1 µg/ml to 100 µg/ml. A 4-hour chromium release assay against T-24 bladder tumor cells. Effector-target cell 
ratio of 40:1 B IFN-γ release was determined by ELISA from supernatants of the stimulated PBMCs C PBMC proliferation was 
measured by overnight 3H-Thymidine incorporation assay (1 µCi/2 × 105 cells). One representative experiment out of 3–6 is 
shown (mean ± SD). n.d. = not detectable
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contrasted by mitogenic stimulation with PHA (figure 2c)
or ConA (not shown) which show an expected peak of
PBMC stimulation at early time points with a subsequent
dramatic decrease.
Dendritic cell activation by PstS1
Dendritic cells are central cellular mediators for the induc-
tion of anti-tumor immune responses. We tested the
potential of PstS1 to induce activation and maturation of
human monocyte-derived DCs.
After 7 days of differentiation human monocyte-derived
dendritic cells showed the typical immature phenotype
with low or absent expression of the monocyte marker
CD14 and the maturation markers CD83 and CD86 (Fig.
3A). At the same time immature DCs expressed high
amounts of CD1a. Stimulation of dendritic cells with
either PstS1 or BCG induced strong upregulation of CD83
and CD86 indicating phenotypical maturation of DC after
challenge with PstS1. In parallel, the cytokine response of
DC was assessed and PstS1 was found to induce substan-
tial amounts of TNF-α and IL-12 p70, two key cytokines
in dendritic cell biology. Interestingly, PstS1 reproducea-
bly induces IL-12p70 in the ng range, while BCG only
induced relatively low levels of IL-12p70 (50–500 pg/ml)
(Fig. 3B).
Intravesical immunotherapy with PstS1 in sensitized and 
non-sensitized mice
After we have shown profound immunostimulatory prop-
erties of PstS1 in vitro we conducted a series of studies to
test its immunotherapeutic potential in vivo. Prompted by
the controversy about the role of prior exposure to myco-
bacterial antigens in BCG immunotherapy we wanted to
assess the in vivo activity of PstS1 in sensitized and non-
sensitized mice. For this purpose two independent in vivo
experiments were carried out. PLG-particles have previ-
ously been described as useful agents for sensitization of
mice to mycobacterial antigens and were used as such in
our study [13].
In a first series of experiments we analyzed mice which
had been s.c. sensitized with empty control particles or
with particles loaded with PstS1 antigen. Ten days later
mice received inoculation of tumor cells and subsequent
intravesical treatment with either PstS1 or PBS control
solution (four weekly instillations). Mice which received
s.c. PBS followed by intravesical PBS served as negative
controls. Using this experimental set up we could show
that pre-vaccination with empty particles and intravesical
treatment with PstS1 protein significantly prolonged sur-
vival of mice and thus provided a clear therapeutic benefit
in this model of experimental bladder cancer (Fig. 4a).
When mice received s.c. injections of PLG-particles fol-
lowed by intravesical control PBS, survival of mice was
marginally increased suggesting a possible minor non-
specific effect of the sensitization procedure (Fig. 4b).
Unexpectedly, antigen-specific sensitization with PstS1-
loaded particles prior to intravesical PstS1 inoculation
completely abrogated the therapeutic effect (Fig. 4c). To
further substantiate the findings of trial one a second trial
with a modified setup was conducted. In this second trial
we compared the effect of s.c. PBS injections, injections of
empty PLG-particles and injections of PLG-particles
loaded with an irrelevant antigen (BSA) on the effect of
intravesical PstS1 treatment. This experimental set up
revealed a modest therapeutic benefit of intravesical PstS1
in the absence of prior sensitization (Fig. 5a). The number
of mice in this experiment was, however, too small to
achieve statistical significance using a stringent log-rank
test (p = 0.1052). When intravesical PstS1 instillations
were combined with pre-vaccination with empty PLG-par-
ticles, the result from the previously described trial was
confirmed and again a clearly prolonged survival of mice
became evident (Fig. 5b). Based on the hypothesis that the
sensitization by itself, irrespective of the antigen used for
sensitization, might have impeded the effect of intravesi-
cal PstS1 in trial one, we tested the effect of particles
loaded with irrelevant BSA protein. However, as shown in
Fig. 5c, the therapeutic effect of PstS1 remained virtually
unchanged suggesting that the inhibition was not due to
the sensitization by itself but rather PstS1 specific.
Local and systemic immune response in PstS1-
immunotherapy
After we had demonstrated successful immunotherapy of
bladder cancer by local instillation of PstS1 we next ana-
lyzed the local and systemic immune response of the var-
ious treatment groups to obtain initial insight into the
immunological basis of this novel immunotherapy. To
achieve this we analyzed the systemic antibody response
by a semiquantitative anti-PstS1 IgG ELISA, the systemic
lymphocyte response by splenocyte restimulation assays
and the local immune response in the bladder by
immunohistology.
As expected no anti-PstS1 IgG response was detected in
the two groups which neither had been sensitized by
PstS1 antigen s.c. nor received intravesical inoculations of
PstS1. On the other hand, both s.c. and intravesical chal-
lenge with PstS1 resulted in positive antibody responses
in every animal of the respective groups. This is an inter-
esting finding as it indicates that systemic anti-PstS1
immune responses cannot only be induced by the well
established s.c. route but also by intravesical instillations
of antigen into the murine bladder (Table 1). Positive
antibody responses were also observed in the group which
received a combination of s.c. PstS1-loaded particles and
intravesical PstS1 and as such failed therapy. A similar pic-
ture was observed with regard to the response ofBMC Cancer 2004, 4:86 http://www.biomedcentral.com/1471-2407/4/86
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Time-course of PBMC stimulation Figure 2
Time-course of PBMC stimulation. PBMC were stimulated with PstS1 (10µg/ml), BCG (4 × 104 CFU/ml), PHA (2,5 µg/ml) 
or left unstimulated. Cytotoxicity (A), IFN-γ-production (B) and proliferation (C) of PBMC were measured after 2, 5 and 7 
days of stimulation. A Cytotoxicity assay. 4-hour chromium release assay against T-24 bladder tumor cells. Effector-target cell 
ratio of 40:1. B IFN-γ release measured by ELISA from culture media of PBMC. C PBMC proliferation measured by overnight 
3H-Thymidine incorporation assay (1 µCi/2 × 105 cells). For A and B one representative experiment out of 3 is shown (mean ± 
SD), for C a composite of seven independent experiments is shown (mean ± SEM). For PHA-stimulation one out of two exper-
iments is shown (mean ± SD) . n.d. = not detectable
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Activation of human monocyte-derived dendritic cells by PstS1 Figure 3
Activation of human monocyte-derived dendritic cells by PstS1. A Monocytes were differentiated for seven days with 
GM-CSF and IL-4 (500 U / ml each), stimulated with BCG (MOI = 0.01) or PstS1 (10 µg / ml) for three days and afterwards 
analyzed by flow cytometry for the expression of CD1a, CD14, CD83 and CD86. Isotype control = filled histograms, specific 
antibody = open histograms. Cells were gated on intact dendritic cells according to forward scatter and sideward scatter. B 
Supernatants of the stimulated DCs were collected and ELISAs for TNF-α and IL-12p70 were performed. One representative 
experiment out of 5 is shown (mean ± SD). n.d. = not detectable.
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Intravesical PstS1 immunotherapy in nonsensitized and PstS1-sensitized mice Figure 4
Intravesical PstS1 immunotherapy in nonsensitized and PstS1-sensitized mice. Ten days before inoculation of MB-
49 tumor cells mice were s.c. sensitized by injection of empty L-particles (A/B) or L-particle loaded with PstS1 (C). On days 1, 
8, 15 and 22 after tumor challenge, mice were treated by intravesical instillation of PstS1 (A/C) or PBS (B). Mice which received 
s.c. PBS and intravesical PBS served as control. Survival of mice was analyzed by Kaplan-Meier curve and log rank test.
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Intravesical PstS1 treatment after sensitization with PBS, PLG-particles or PLG-particles/BSA Figure 5
Intravesical PstS1 treatment after sensitization with PBS, PLG-particles or PLG-particles/BSA. Ten days before 
inoculation of MB-49 tumor cells mice were s.c. sensitized by injection of PBS (A), L-particles (B) or L-particles loaded with 
BSA (C). On days 1, 8, 15 and 22 after tumor challenge, mice were treated by intravesical instillation of PstS1 (A/B/C). Mice 
which received s.c. PBS and intravesical PBS served as control. Survival of mice was analyzed by Kaplan-Meier curve and log 
rank test.
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restimulated splenocytes (Fig. 6). The two groups of mice
with no prior contact to PstS1 only minimally responded
to in vitro stimulation with PstS1. In contrast, the four
groups of mice which had been exposed to PstS1 either
s.c. or intravesically or via both routes strongly responded
to specific restimulation of their splenocytes. Again these
data indicate that systemic immune responses to PstS1
can be achieved by both s.c. and intravesical challenge.
While a s.c. sensitization of mice with PstS1 abrogated the
anti-tumor effect of intravesical PstS1 (see Fig. 4) the sys-
temic immune response was not negatively affected but
even enhanced in some animals (see Fig. 6).
After the analysis of the systemic immune response to
PstS1 we continued our experiments with an immunohis-
tological study of the local immune response. To this end
we specifically looked at the influx of lymphocytes, den-
dritic cells, macrophages and granulocytes (table 2). As
expected, bladders of control mice with no PstS1
injections (groups 1–2) were only minimally infiltrated
by granulocytes (Gr-1 antigen) or CD11b-positive cells
(activation marker for granulocytes and macrophages).
On the other hand, after local instillation of PstS1 a
distinct influx of granulocytes and macrophages was
observed (groups 4–5, table 2). This cellular infiltration of
the bladder with granulocytes and macrophages was not
substantially altered by additional sensitization of the
mice with PstS1-loaded particles (group 6, table 2). In
contrast to what is known about classical immunotherapy
with BCG [24], challenge of mice with PstS1 only induced
a moderate infiltration of the bladder with CD4-positive
lymphocytes (groups 4–5, table 2). A slight increase in the
number of CD8-positive cells was noted in mice which
received s.c. PstS1 sensitization in addition to intravesical
PstS1 (group 6, table 2). Dendritic cells (CD11c) were a
rare cell population in control mice without PstS1 injec-
tions (groups 1–2). A slightly increased number of den-
dritic cells was noted in the bladders of mice after
intravesical instillation of PstS1. Nonetheless, the overall
local immune response in the bladder during PstS1
immunotherapy is clearly dominated by the influx of
granulocytes and macrophages. A certain induction of
local bladder cellularity was also noted in mice which
received s.c. injections of PstS1 but no intravesical instil-
lation of the antigen (group 3). The reason for this effect
of s.c. PstS1 injection on bladder cellularity is unclear.
Table 2: Local immune response in the bladder wall after PstS1 immunotherapy
group S.C. / Intravesical Treatment CD11b GR-1 CD4 CD8 CD11c
1 PBS/PBS 11± 8 3 ± 2 28 ± 24 8 ± 9 2,2 ± 1,7
2 L-Particle/PBS 6 ± 7 3 ± 2 17 ± 6 4 ± 3 1,6 ± 1,4
3 L-Particle-PstS1/PBS 24 ± 20 4 ± 7 69 ± 60 16 ± 15 22,2 ± 24,4
4 PBS/PstS1 86 ± 46 44 ± 30 45 ± 18 10 ± 4 1,9 ± 2,1
5 L-Particle/PstS1 114 ± 25 56 ± 20 56 ± 16 13 ± 14 3 ± 2,4
6 L-Particle-PstS1/PstS1 143 ± 84 49 ± 15 75 ± 29 36 ± 29 4,5 ± 4,2
Five mice per group were sensitized s.c. and treated intravesically on days 10, 17, 24 and 31 as indicated in the table. On day 32 bladders were 
dissected and used for histochemistry. CD11b: Granulocytes and Macrophages, GR-1: Granulocytes, CD4: CD4-Lymphocytes, CD8: CD8-
Lymphocytes, CD 11c: Dendritic cells. The number of positive cells in the entire bladder specimens was counted using visual fields and light 
microscopy. The data are depicted as the mean number of positive cells per visual field ± standard deviation (n = five mice per group).
Splenocyte Restimulation Figure 6
Splenocyte Restimulation. Treatment of mice was per-
formed as indicated (s.c. sensitization / intravesical instilla-
tion). One day after the fourth intravesical PstS1 treatment 
splenocytes were isolated and restimulated with PBS as con-
trol (open circles) or 10 µg/ml PstS1 (filled boxes) for five 
days and proliferation was analyzed by 3H-Thymidine incor-
poration assay.
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Discussion
BCG therapy is a clinically successful therapy in the treat-
ment of bladder cancer but its acceptance is hampered by
hazards and side effects related to the use of viable
mycobacteria. The aim of this study was to evaluate the
anti-tumor potential of the well-defined, non-viable
mycobacterial antigen PstS1.
To this end we first tested the potential of recombinant
PstS1 to activate human PBMC cultures. In this series of
experiments PstS1 induced strong cytotoxicity, prolifera-
tion and IFN-γ production in human PBMC. Ten µg/ml
PstS1 were found to be optimal for activation of human
PBMC. We used BCG lyophilisate as a reference stimulus
in these experiments as we have previously described BCG
as a potent activator of human PBMC functions [27].
PstS1 followed a similar time kinetic as BCG in the stimu-
lation of human PBMC, albeit activation of PBMC func-
tions was somewhat lower with PstS1 compared with
BCG. PstS1 was previously shown to induce profound cel-
lular immunity in different vaccination studies [28-30].
Therefore, our results further confirm the potential of
PstS1 to function as a potent inducer of T-helper 1 and
cell-mediated immune responses.
While IFN-γ is a key cytokine in TH1 immune responses
produced by activated lymphocytes, IL-12 is mainly
produced by monocytes/macrophages as well as dendritic
cells and important in the early phase of cellular
immunity [31]. IL-12 is a potent inducer of anti-tumor
immunity [32] and acts together with IFN-γ and TNF-α in
a positive feedback loop [25,33,34]. Although BCG myco-
bacteria are relatively weak inducers of bioactive IL-12p70
in human dendritic cells in the absence of additional
costimulation like CD154 or IFN-γ (figure 3b), IL-12 has
been shown to be essential for therapeutic efficacy in
experimental BCG immunotherapy of bladder cancer
[24]. Given the importance of dendritic cells for the initi-
ation of anti-tumor immune responses [35] and as a
source of IL-12 and TNF-α we tested the capacity of
recombinant PstS1 to activate human monocyte-derived
dendritic cells. Our results clearly identified PstS1 as a
potent stimulator of human DCs as it provoked upregula-
tion of CD83 and CD86 surface expression as well as
induction of cytokines. Of interest is the expression of
high amounts of bioactive IL-12 after stimulation of DCs
with PstS1 as only small amounts of this cytokine are pro-
duced after challenge with BCG or other mycobacterial
antigens (figure 3 and unpublished observations).
The encouraging in vitro experiments then prompted us to
evaluate the immunotherapeutic potential of PstS1 in a
well-established murine model of experimental bladder
cancer [20]. The effect of prior sensitization or
responsiveness to mycobacterial antigens for the effective-
ness and outcome of subsequent immunotherapy with
BCG is still a matter of intensive debate [21-23]. Taking
this into account we took advantage of the fact that we
had in hand a well-defined, recombinant antigen already
evaluated in vaccination studies against mycobacterial
infections and included a prime-boost treatment regimen
into our experimental immunotherapy protocol. The
main objective of our series of in vivo experiments was to
determine the anti-tumor potential of local instillations of
recombinant PstS1 and to compare the effect of intravesi-
cal PstS1 in sensitized and non-sensitized mice. Because
adsorption of PstS1 to L-particles has previously been
described as very efficient in inducing specific cellular
immunity to this antigen [29], we adopted this method of
sensitization for our treatment protocol. Using a protocol
of four weekly instillations of PstS1 into the bladder
(adopted from the treatment schedule in use for immuno-
therapy with BCG) we observed a strong therapeutic effect
of PstS1 instillations. Intravesical PstS1 significantly pro-
longed survival of mice and induced systemic immune
responses and cellular infiltration of the bladder with
different subpopulations of leukocytes. The anti-tumor
effect of PstS1 was already evident after intravesical instil-
lation of PstS1 only but was further enhanced after s.c.
injection of empty L-particles (Fig. 5). Unexpectedly, sen-
sitization of mice with PstS1-loaded particles almost com-
pletely abrogated the therapeutic effect of intravesical
PstS1 (Fig. 4). In order to test whether the negative effect
of prior sensitization was specific for PstS1 or could also
be induced by s.c. injection of L-particles loaded with an
irrelevant antigen, we compared the therapeutic effect of
intravesical PstS1 combined with a) s.c. sensitization with
BSA-loaded L-particles, b) s.c. injection of empty L-parti-
cles and c) s.c. injection of PBS only (Fig. 5). Clearly, the
injection of BSA-loaded particles did not influence the
therapeutic effect of intravesical PstS1 indicating that only
PstS1-specific previous sensitization is detrimental (Fig.
5a and 5c). We analyzed the systemic serum antibody
response, activation of splenocytes and the local cellular
infiltration of the bladder wall in sensitized and non-sen-
sitized mice (Fig. 6) in order to understand and explain
the remarkable therapeutic potential of intravesical PstS1
as well as the negative effect of prior specific sensitization.
Interestingly, even without sensitization, instillation of
PstS1 into the bladder provoked a systemic anti-PstS1
response visualized by murine anti-PstS1 serum antibod-
ies and splenocyte proliferation after rechallenge in vitro.
In addition to this systemic immune activation, intravesi-
cal PstS1 also induced the local influx of lymphocytes,
macrophages and granulocytes into the bladder. While
only a minimal influx of CD8-cells could be observed
after instillation of PstS1, a considerable infiltration of the
bladder with granulocytes, macrophages and CD4-cells
was noted. Although prior specific sensitization with
PstS1 completely abrogated the anti-tumor effect of intra-BMC Cancer 2004, 4:86 http://www.biomedcentral.com/1471-2407/4/86
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vesical PstS1, the cellular infiltration of the bladder wall
remained essentially unchanged when comparing sensi-
tized and non-sensitized animals. In the splenocyte res-
timulation assay an enhanced response of two out of four
mice was noted in the group of mice which received s.c.
PstS1 followed by intravesical PstS1 compared with the
two groups which received either treatment alone (Fig. 6).
This indicates that the combination of s.c. sensitization
and intravesical treatment indeed augmented the systemic
immune response at least in some animals. Surprisingly,
this enhanced systemic immune response coincided with
an abrogation of tumor-therapeutic efficacy. A possible
explanation for this phenomenon could be that the anti-
PstS1 antibodies, which were induced after s.c. priming
would bind to the recombinant PstS1 shortly after instil-
lation into the bladder and thereby neutralize its function
and anti-tumor effect. However, as mentioned earlier,
even in the PstS1-specific prime-boost treatment regimen
an unchanged cellular infiltration of the bladder wall was
noted. Alternatively, the sensitization might render the
subsequent local immunotherapeutic immune response
insufficient, because the host immune system is still
actively responding to the priming at the onset of immu-
notherapy. This situation might be called "immune
exhaustion" making the host unable to mount a sufficient
local anti-tumor immune response while still responding
to the specific priming. Further experiments are needed to
clarify whether a modification of the time schedule of
such a "prime-immunotherapy" protocol could prevent
the negative effects observed in this study and might even
enhance immunotherapy with PstS1.
Nonetheless, our combined in vitro and in vivo analyses
clearly identified PstS1 from M. tuberculosis as a potent
immunostimulant and a potential immunotherapeutic
anti-cancer agent for topical treatment strategies. Our data
do not show and do not imply that PstS1 is the major or
only immunostimulatory component of whole BCG
mycobacteria in BCG immunotherapy of bladder cancer.
Conclusions
We have identified the immunodominant mycobacterial
PstS1 antigen as a potent biological response modifier for
tumor immunotherapy. Using a human in vitro system of
PBMC activation and a murine model of experimental
bladder cancer immunotherapy we could show strong
immunostimulatory capacity of PstS1 as well as signifi-
cant anti-tumor activity. In a model of prime-boost
immunotherapy we observed that antigen-specific sensiti-
zation might jeopardize the positive effects of topical
immunotherapy and therefore has to be considered and
evaluated with caution. GMP-production of PstS1 and a
clinical trial in humans is currently being established and
might open the door for an efficient and safe alternative
in the field of bladder cancer immunotherapy.
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